SCHEMBL16632291

SCHEMBL16632291

CCc1nc2cc(NCCc3ccc(OC)cc3)ncc2cc1-c1cc(NC(=O)O)c(F)cc1F

nearest known ligand 0.42

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
HDAC1 Q13547 1/20 0.42
PTGDR Q13258 5/20 0.41
ABL1 P00519 1/20 0.40
KDR P35968 9/20 0.39
FGFR1 P11362 8/20 0.39
RAF1 P04049 2/20 0.38
BRAF P15056 2/20 0.38
KRAS P01116 1/20 0.38
MAP2K2 P36507 1/20 0.38
MAP2K1 Q02750 1/20 0.38
FLT1 P17948 5/20 0.38
FGFR2 P21802 5/20 0.38
FGFR4 P22455 5/20 0.38
FGFR3 P22607 5/20 0.38
FLT4 P35916 5/20 0.38
ARAF P10398 1/20 0.37
MAP2K7 O14733 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16632422 0.94 KDR (0.44) HDAC1PTGDRABL1KDRFGFR1
SCHEMBL16632379 0.92 KDR (0.46) HDAC1PTGDRKDRFGFR1RAF1
SCHEMBL16632181 0.89 PTGDR (0.46) HDAC1PTGDRABL1KDRFGFR1
SCHEMBL16632504 0.86 KDR (0.53) HDAC1PTGDRABL1KDRFGFR1
SCHEMBL16632292 0.82 ALDH1A1 (0.36) HDAC1ABL1KDRFGFR1RAF1
SCHEMBL16632239 0.79 KDR (0.43) HDAC1PTGDRKDRFGFR1RAF1
SCHEMBL16632423 0.76 KDR (0.38) HDAC1ABL1KDRFGFR1RAF1
SCHEMBL16632209 0.75 KDR (0.53) ABL1KDRFGFR1RAF1BRAF
SCHEMBL16632300 0.75 RAF1 (0.53) HDAC1PTGDRKDRFGFR1RAF1
SCHEMBL15289506 0.74 ABL1 (0.35) HDAC1ABL1KDRFGFR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9187474-B2 Raf inhibitor compounds DECIPHERA PHARMACEUTICALS, LLC (US) 2015-11-17 US disclosed
US-20150105367-A1 RAF INHIBITOR COMPOUNDS DECIPHERA PHARMACEUTICALS, LLC 2015-04-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150105367-A1 RAF INHIBITOR COMPOUNDS BRAF, RAF1, NRAS HDAC1 440/4885PTGDR 4299/4885ABL1 56/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.